emerg
reemerg
infecti
diseas
expand
global
threat
public
health
secur
economi
increas
popul
urban
deforest
climat
chang
antivaccin
movement
war
intern
travel
contribut
factor
trend
recent
ebola
merscov
zika
outbreak
demonstr
insuffici
prepar
respond
proven
safe
effect
countermeasur
ie
vaccin
therapeut
state
univers
new
york
upstat
medic
univers
trudeau
institut
conven
summit
key
opinion
thought
leader
life
scienc
biomed
research
develop
enterpris
explor
global
bioprepared
challeng
take
inventori
exist
capabl
capac
relat
prepar
respons
assess
current
gap
prospect
could
done
improv
posit
herein
describ
summit
proceed
translat
immunolog
support
biomed
countermeasur
develop
emerg
vectorborn
viral
diseas
held
octob
trudeau
institut
saranac
lake
ny
trudeau
institut
saranac
lake
ny
partnership
state
univers
new
york
upstat
medic
univers
syracus
ny
host
summit
entitl
translat
immunolog
support
biomed
countermeasur
develop
emerg
vectorborn
viral
diseas
attende
includ
basic
scientist
physicianscientist
scienc
support
profession
organ
institut
experi
expertis
identifi
work
solv
major
global
health
problem
mission
defin
today
press
global
health
problem
identifi
critic
obstacl
challeng
develop
solut
problem
prospect
may
overcom
summit
session
focus
diseas
prepared
vaccin
develop
summit
organ
desir
catalyz
format
sustain
product
strateg
interdisciplinari
partnership
collabor
research
network
focu
rapid
develop
countermeasur
press
global
health
threat
three
keynot
speaker
repres
intern
vaccin
institut
ivi
coalit
epidem
prepared
innov
cepi
us
nation
institut
health
nih
frame
four
concept
area
discuss
two
individu
session
per
topic
session
defin
specif
topic
led
preselect
session
leader
overal
organ
present
box
first
concept
discuss
identifi
prepar
diseas
x
refer
next
major
infecti
diseas
epidem
pandem
dr
melani
savil
director
vaccin
develop
cepi
introduc
concept
discuss
possibl
diseas
x
pathogen
stress
may
current
known
unknown
may
includ
known
threat
ebola
known
virus
unrecogn
impact
zika
unknown
threat
previous
identifi
current
global
trend
indic
new
diseas
emerg
everi
four
month
like
diseas
x
emerg
zoonot
origin
nearli
pandem
fit
model
need
identifi
burgeon
outbreak
initi
develop
countermeasur
stress
cite
key
exampl
flu
pandem
model
vaccin
model
initi
present
recent
gate
foundat
pandem
occur
today
major
citi
world
would
impact
million
dead
within
day
recent
exampl
coordin
global
respons
west
africa
ebola
pandem
challeng
field
test
therapeut
vaccin
candid
review
ebola
respons
produc
four
key
recommend
strengthen
humananim
surveil
system
first
line
defens
reinforc
global
coordin
capabl
acceler
product
develop
provid
econom
incent
help
path
prevent
global
health
disast
diseas
x
global
prepar
draw
exist
public
health
organ
togeth
coordin
vigor
sustain
effort
deliv
safe
effect
vaccin
need
import
cepi
goal
address
prepared
rapid
respons
diseas
x
leverag
predevelop
vaccin
platform
inject
formul
dna
selfrepl
rna
recombin
protein
viral
vector
recogn
howev
regul
licens
vaccin
platform
even
use
wellestablish
platform
rapid
vaccin
develop
emerg
viru
may
allow
rapid
regulatori
approv
regulatori
agenc
vari
global
howev
use
predevelop
platform
could
expedit
path
preclin
research
clinic
develop
current
slow
comprehens
respond
emerg
reemerg
outbreak
biosurveil
high
risk
area
need
bolster
deploy
sustain
diagnost
platform
datashar
capabl
effect
collabor
key
success
bioprepared
respons
share
understand
situat
graviti
effect
commun
among
stakehold
essenti
prepared
improv
mani
area
includ
standard
anim
model
leverag
vaccin
construct
platform
grow
clinic
trial
capabl
high
risk
area
leverag
expand
global
biomanufactur
capabl
develop
deploy
analyt
assay
streamlin
regulatori
pathway
note
ad
review
concept
discuss
herein
diseas
x
limit
vector
born
diseas
deliber
chose
includ
human
engin
bioterror
agent
encount
natur
felt
adequ
consider
would
includ
separ
full
discuss
intellig
gather
countermeasur
mitig
bioprepared
would
beyond
scope
meet
agenda
keynot
address
serv
introduct
two
ensu
discuss
session
first
global
biosurveil
enterpris
infrastructur
improv
better
support
bioprepared
respons
led
col
matt
hepburn
us
depart
defens
defens
advanc
research
project
agenc
darpa
session
take
home
point
assess
well
global
health
commun
current
achiev
effect
biosurveil
glass
appear
half
empti
half
full
modern
technolog
next
gener
sequenc
ng
wide
implement
diagnosi
track
infecti
diseas
howev
room
improvementleverag
full
potenti
technolog
hinder
sever
factor
group
work
isol
ie
share
data
time
manner
limit
access
sampl
countri
effect
outbreak
failur
captur
annot
critic
inform
time
precis
locat
sampl
collect
box
overal
organ
concept
next
emerg
diseas
diseas
x
keynot
identifi
prepar
diseas
x
discuss
global
biosurveil
enterpris
infrastructur
improv
better
support
bioprepared
respons
discuss
global
biosurveil
enterpris
infrastructur
improv
better
support
develop
univers
flu
vaccin
assess
need
neglect
popul
pregnant
women
infant
etc
concept
opportun
preclin
develop
keynot
futur
invest
anim
model
discuss
model
keep
discard
model
deliv
one
continu
deceiv
discuss
preclin
model
support
countermeasur
develop
suggest
improv
global
biosurveil
enterpris
transit
monitor
advanc
specif
outbreak
time
vertic
surveil
horizont
surveil
quantifi
presenc
divers
pathogen
across
popul
time
anoth
suggest
creat
standard
criteria
assess
global
viral
threatstrop
replic
structur
genotyp
evolut
immun
evas
pathogenesi
anim
model
correl
protect
howev
may
difficult
virus
util
rang
host
vector
etc
achiev
ultim
goal
fulli
implement
global
health
biosurveil
proactiv
instead
reactiv
imper
solv
problem
sustain
fund
gener
consensu
group
topic
produc
blueprint
sustain
fund
continu
horizont
global
biosurveil
futur
discuss
bioprepared
need
includ
expert
financ
ethic
intern
polit
addit
biomed
scientist
clinician
product
develop
second
discuss
session
focus
singl
global
infecti
diseas
threatinfluenza
dr
bruce
inni
program
appropri
technolog
health
path
led
discuss
global
biosurveil
enterpris
infrastructur
improv
better
support
develop
univers
influenza
vaccin
assess
need
special
popul
ie
pregnant
women
elderli
infant
etc
session
take
home
point
influenza
affect
differ
popul
differ
group
ask
question
effect
way
quantifi
frailti
alert
us
need
close
monitor
flu
season
vaccin
influenza
benefici
modifi
infect
outcom
addit
prevent
diseas
clinic
trial
univers
influenza
vaccin
candid
implement
valid
sever
score
children
adult
captur
full
valu
intervent
metric
provid
sever
score
develop
valid
sustain
multiyear
clinic
trial
mani
import
question
relat
natur
histori
influenza
infect
popul
address
exampl
rel
efficaci
individu
preexist
immun
natur
season
vaccin
versu
children
impact
coinfect
pathogen
outbreak
influenza
possibl
achiev
sustain
protect
exposur
multipl
strain
year
import
object
face
stiff
realiti
import
endpoint
beyond
strictli
requir
licensur
difficult
incorpor
alreadi
expens
logist
challeng
trial
establish
field
site
low
middleincom
countri
longitudin
surveil
respiratori
diseas
would
build
globallybenefici
diseas
surveil
vaccin
evalu
capac
concept
introduc
dr
cristina
cassetti
nih
highlight
recent
outbreak
ebola
zika
experi
help
identifi
area
improv
includ
surveil
global
scale
earli
detect
transpar
improv
commun
build
infrastructur
capac
better
coordin
basic
clinic
research
make
platform
technolog
nimbl
adapt
find
stabl
sourc
fund
dr
cassetti
outlin
overal
approach
achiev
success
prepared
base
strateg
logist
financi
scientif
singl
import
strateg
compon
enhanc
collabor
global
partner
partnership
must
exist
prior
outbreakwith
mutual
trust
nih
collabor
center
cepi
us
feder
govern
particip
public
health
emerg
medic
countermeasur
enterpris
phemc
also
import
establish
relationship
local
ministri
health
exemplar
advanc
includ
logist
emerg
outbreak
standard
oper
procedur
sop
develop
financi
mechan
urgent
parent
fund
opportun
announc
foa
releas
fall
establish
allow
supplement
exist
grant
issu
streamlin
broad
agenc
announc
baa
contract
process
also
util
scientif
new
vaccin
platform
technolog
leverag
specif
anim
model
need
develop
new
anim
model
differ
use
onesizefit
discuss
develop
highli
character
pathogen
strain
assay
model
gener
data
could
use
support
nontradit
regulatori
approv
pathway
discuss
nih
current
develop
integr
plan
respond
emerg
threat
plan
base
prototyp
approach
viral
famili
implic
human
diseas
new
virus
like
emerg
eg
zoonot
rna
virus
etc
evalu
identifi
repres
pathogen
prototyp
famili
systemat
supportconduct
research
fill
knowledg
gap
need
support
countermeasur
develop
prototyp
eg
mechan
pathogenesi
protect
immun
suitabl
anim
model
develop
candid
vaccinestherapeut
toward
evalu
anim
model
phase
test
build
integr
network
clinic
site
around
world
promis
countermeasur
could
rapidli
test
field
safeti
efficaci
infect
studi
natur
set
human
vector
natur
histori
studi
addit
niaid
effort
improv
bioprepared
includ
develop
relev
anim
model
recapitul
human
diseas
enabl
studi
human
pathophysiolog
continu
develop
ex
vivo
model
brain
organoid
continu
focu
critic
gap
pathogen
identificationc
haracter
pathogenesi
point
reiter
need
strengthen
intern
clinic
trial
capac
attempt
better
align
regulatori
agenc
review
requir
develop
flexibl
fund
mechan
first
discuss
session
concept
anim
modelsmodel
keep
discard
model
deliv
one
continu
deceiv
led
dr
alan
barrett
univers
texa
medic
branch
galveston
session
take
home
point
translat
discoveri
scienc
preclin
develop
anim
model
straightforward
anim
model
ideal
recapitul
human
diseas
overal
valu
anim
model
evalu
drug
vaccin
candid
requir
high
qualiti
well
character
prefer
standard
valid
assay
reagent
challeng
materi
spectrum
similar
anim
human
immun
system
respons
infect
differ
must
taken
account
interpret
preclin
data
make
programmat
decis
base
anim
model
inform
dose
select
human
studi
howev
remain
varianc
across
model
respons
may
overor
underestim
expect
human
exampl
nonhuman
primat
respons
ebola
vaccin
candid
overestim
human
respons
infer
protect
immun
respons
human
base
natur
infect
pathogenfre
anim
precari
especi
true
explor
correl
protect
one
may
pay
particular
attent
differ
pathogen
deliv
natur
ie
mosquito
superfici
dermi
salivari
protein
may
may
translat
depend
deliv
context
vaccin
ie
needl
intramuscular
subcutan
salivari
protein
note
ad
review
back
correl
efficaci
vaccin
mechan
protect
carri
deriv
correl
protect
altern
approach
use
vitro
organoid
ex
vivo
studi
use
supplement
live
anim
model
although
role
support
product
develop
uncertain
sever
paramet
anim
model
poorli
reflect
human
infect
diseas
experi
exampl
time
cours
infect
anim
model
remark
differ
human
lethal
challeng
model
eg
nipah
provid
endpoint
suitabl
translat
clinic
trial
model
relev
also
discuss
context
zika
pregnanc
model
immunocompet
mice
infect
dam
get
viremia
detect
vertic
transmiss
viru
yet
virtual
fetal
demis
monoclon
antibodi
block
studi
indic
despit
absenc
product
infect
patholog
appar
caus
viru
rais
possibl
fetal
demis
due
specif
placent
patholog
would
great
valu
develop
high
qualiti
standard
anim
model
challeng
strain
particular
pathogen
broadli
accept
follow
good
laboratori
practic
within
high
biocontain
requir
handl
pathogen
difficult
could
impact
countermeasur
develop
effort
area
note
ad
review
emphasi
place
work
biocontain
lab
get
close
glp
complianc
possibl
candid
vaccin
drug
enter
clinic
test
proven
safe
effect
would
valuabl
go
back
assess
preclin
anim
model
support
support
inform
programmat
decis
make
second
discuss
session
concept
preclin
develop
led
dr
kent
kester
sanofi
pasteur
topic
innov
preclin
model
support
countermeasur
develop
session
take
home
point
ex
vivo
model
potenti
chang
countermeasur
develop
paradigm
support
move
investig
product
clinic
trial
faster
produc
inform
relev
data
eg
antigen
concentr
overal
formul
select
partner
ex
vivo
immunolog
model
develop
experiment
human
infectionchalleng
model
tool
could
also
particularli
import
area
explor
especi
clear
surrog
correl
protect
identifi
ex
vivo
model
use
support
regul
activ
remain
unknown
requir
consider
explor
countermeasur
develop
sponsor
need
engag
regulatori
author
explor
ex
vivo
human
immun
model
appropri
substitut
anim
studi
level
evid
accept
ex
vivo
human
organ
system
model
may
valu
especi
studi
diseas
specif
characterist
may
make
difficult
studi
context
natur
infect
ie
long
incub
period
period
occurr
etc
vaccin
proven
safe
efficaciouseffect
provid
excel
opportun
explor
potenti
mechan
action
correl
surrog
protect
countermeasur
applic
relat
similar
pathogen
also
potenti
explor
physiolog
immunolog
situat
reproduc
ex
vivo
system
subsequ
appli
new
explor
note
ad
review
invers
abil
ex
vivo
system
predict
safetyreactogen
issu
import
topic
introduc
keynot
present
jerom
kim
director
gener
intern
vaccin
institut
discuss
prospect
expand
global
biomanufactur
execut
clinic
trial
dr
kim
present
comprehens
overview
hurdl
involv
deliveri
success
global
health
vaccin
site
outbreak
includ
innov
gap
discoverypreclin
phase
translat
gap
prior
clinic
develop
implement
gap
affect
polici
uptak
present
exampl
rotaviru
illustr
impedi
dissemin
vaccin
subsequ
develop
includ
access
cost
also
talk
fund
povertyassoci
infecti
diseas
littl
market
incent
develop
propos
combin
pharma
philanthropi
govern
develop
publicpriv
partnership
vaccin
develop
fund
session
take
home
point
current
fund
model
need
transit
epidemicrespons
fund
sustain
fund
model
incentiv
countermeasur
develop
anticip
expenditur
develop
countermeasur
neglect
diseas
match
larger
valu
proposit
derisk
develop
proposit
newer
tool
ex
vivo
human
challeng
adapt
design
lower
cost
time
market
may
help
comprehens
analysi
global
financ
vaccin
marketshar
need
creat
maintain
countermeasur
develop
continu
plagu
inadequ
innov
prediscoveri
space
poor
translat
clinic
sloppi
implement
bioproduct
distribut
commerci
sector
innov
creat
oper
effici
incentiv
captur
element
global
vaccin
develop
valu
chain
global
commun
need
understand
leverag
increas
capac
biomanufactur
develop
emerg
market
ensur
reproduc
safeti
qualiti
note
ad
review
public
incent
option
biomanufactur
may
help
case
privat
market
fail
platform
technolog
develop
may
aid
develop
next
discuss
led
john
mascola
vaccin
research
center
niaid
built
upon
issu
introduc
dr
kim
keynot
present
address
critic
path
obstacl
gap
advanc
first
human
clinic
endpoint
studi
discuss
organ
four
topic
scientif
gap
limit
good
manufactur
practic
gmp
capabl
capac
regulatori
issu
limit
clinic
trial
infrastructur
group
conclud
major
limit
rapid
advanc
vaccin
inabl
plan
execut
full
product
develop
plan
start
finish
includ
necessari
end
end
fund
session
take
home
point
session
led
jame
f
cum
icon
govern
public
health
solut
contract
research
organ
cro
optim
suboptim
util
support
countermeasur
develop
opportun
improv
cro
cover
broad
rang
clinic
trial
activ
includ
trial
design
manag
enhanc
recruit
collect
process
clinic
sampl
data
collect
manag
analysi
develop
document
registr
dr
cum
provid
numer
exampl
cro
offer
resourc
supplement
develop
program
includ
flexibl
staf
support
clinic
trial
medic
technic
document
intellectu
properti
issu
file
registr
global
reach
flexibl
staf
contribut
product
help
organ
manag
risk
function
servic
provis
fsp
staf
clinic
oper
span
preclin
studi
file
market
approv
cro
offer
complet
packag
cro
also
use
issu
aris
intern
set
unexpect
polit
regulatori
issu
corrupt
cultur
issu
cro
wellestablish
intern
partner
act
site
mainten
organ
cro
contract
network
individu
provid
host
nation
umbrella
cro
session
take
home
point
cro
particip
broad
spectrum
r
activ
enhanc
acceler
vaccin
develop
creat
standard
case
definit
data
captur
platform
report
system
data
transmiss
regulatori
file
cro
offer
manufactur
perspect
includ
global
databas
avail
manufactur
capac
base
platform
experi
term
engag
avail
monitor
manag
ownership
cro
regulatori
expertis
fill
gap
knowledg
bandwidth
experi
effect
approach
regulatori
agenc
european
medicin
agenc
europ
ema
us
food
drug
administr
us
fda
cro
help
deal
intern
site
base
past
experi
experienc
cro
develop
larg
simpl
studi
appropri
auster
environ
know
dispens
complex
assess
need
done
context
done
session
prospect
nontradit
path
demonstr
safeti
clinic
benefit
countermeasur
led
tom
monath
crozet
biopharma
key
point
cover
includ
effect
antigen
drift
surveil
innov
safeti
assess
implement
anim
rule
use
immun
biomark
evalu
clinic
efficaci
ethic
challeng
human
challeng
model
licensur
standard
wildlif
vaccin
session
take
home
point
antigen
drift
lead
multitud
issu
impact
assess
clinic
benefit
vaccin
antibodi
therapi
includ
defin
protect
epitop
across
mani
clinic
isol
determin
establish
firm
evid
clinic
relev
evalu
cross
protect
anim
use
monoclon
antibodi
mediat
neutral
vitro
cogniz
potenti
confound
effect
vitro
neutral
use
calibr
vaccin
dose
japanes
enceph
vaccin
exampl
issu
group
felt
littl
evid
import
role
toxicolog
studi
modifi
develop
plan
howev
neg
toxicolog
studi
may
support
advanc
candid
newer
method
assess
safeti
might
includ
replac
tradit
toxicolog
studi
innov
technolog
organ
chip
imag
data
rather
biodistribut
anim
rule
current
reserv
situat
efficaci
difficult
unlik
time
sensit
window
prove
human
phase
improv
effect
anim
rule
global
scale
suggest
u
leader
anim
rule
regul
await
us
approv
suggest
consider
given
hybrid
modelhow
relev
anim
data
link
supplement
human
data
use
immun
biomark
evalu
clinic
efficaci
consid
import
timesav
step
demonstr
clinic
benefit
concept
impli
function
attribut
immuneprotect
respons
use
immun
marker
support
acceler
approv
pathway
desir
howev
mani
unansw
question
mechan
protect
vaccin
neutral
antibodi
correl
mani
virus
shown
unreli
case
examplesebola
dengu
may
import
studi
survivor
immun
respons
potenti
role
biomark
identifi
advers
eventsfor
exampl
biomark
could
present
opportun
predict
reactogen
adjuv
passiv
immun
valuabl
tool
establish
role
antibodi
protect
determin
seroprotect
level
exampl
passiv
transfer
arenaviru
model
use
establish
neutral
nonneutr
antibodi
protect
ethic
challeng
complic
placebo
control
test
vaccin
life
threaten
infect
well
use
human
challeng
model
exampl
use
random
control
trial
rct
ebola
outbreak
highli
controversi
innov
approach
step
wedg
method
delay
ring
vaccin
taken
control
vaccin
trial
efficaci
success
demonstr
incorpor
human
challeng
model
vaccin
develop
diseas
x
high
mortal
done
given
avail
partial
attenu
vaccin
viru
pseudotyp
attenu
viru
challeng
oper
consider
harm
specif
instanc
studi
cross
protect
antigenicallyrel
viru
strategi
emerg
exampl
use
approv
japanes
enceph
vaccin
west
nile
chikungunya
vaccin
nyong
nyong
licensur
standard
need
establish
order
acceler
approv
vaccin
adopt
standard
substanti
effect
evid
reason
likelihood
clinic
benefit
valuabl
fda
shown
willing
grant
licensur
pandem
influenza
manufactur
similar
mechan
season
flu
vaccin
note
ad
review
howev
manufactur
facil
requir
pose
challeng
associ
valid
new
process
facil
vaccin
anim
respons
transmiss
agent
human
effect
tool
combat
spread
pandem
therefor
import
understand
natur
histori
diseas
exampl
given
access
anim
play
role
amplif
could
vaccin
interrupt
human
outbreak
exampl
venezuelan
equin
enceph
rift
valley
fever
nipah
viru
diseas
importantli
veterinari
vaccin
faster
easier
develop
usda
grant
condit
approv
pathway
despit
success
approach
control
rabi
wildlif
vaccin
remain
virtual
unexplor
mani
opportun
learn
experi
import
assess
effect
evid
vaccin
failur
effort
make
use
studi
protect
subclin
mild
infect
find
clue
correl
protect
case
use
focu
develop
resourc
effect
use
jennerian
cross
reactiv
vaccin
event
emerg
eg
chikungunya
vaccin
vs
nyong
nyong
japanes
enceph
vaccin
vs
west
nile
note
ad
review
anim
rule
reserv
drug
vaccin
tradit
acceler
approv
pathway
possibl
directli
relat
timesensit
window
prove
efficaci
phase
trial
also
preclin
toxicolog
studi
may
use
neg
toxicolog
find
affect
decis
pursu
product
develop
box
overarch
recommend
strengthen
breadth
depth
humananim
diseas
surveil
entomologist
veterinarian
engag
physician
scientist
studi
human
diseas
reinforc
standard
incentiv
global
coordin
realtim
accur
data
share
expand
global
clinic
trial
capac
especi
area
emerg
reemerg
infecti
diseas
improv
preclin
anim
model
strive
accur
recapitul
natur
pathogen
deliveri
human
infect
respons
patholog
outcom
strateg
invest
explor
ex
vivo
model
diseas
especi
assess
correlatessurrog
protect
countermeasur
proven
safe
effect
human
futur
discuss
bioprepared
need
includ
expert
financ
ethic
intern
polit
addit
biomed
scientist
clinician
product
develop
standard
regulatori
requir
intern
think
innov
licensur
requir
pathogen
tradit
clinic
endpoint
studi
may
possibl
develop
fund
strategi
provid
endtoend
secur
fund
scenario
develop
effort
incentiv
invest
reduc
risk
reward
effici
deliver
continu
explor
opportun
use
experiment
human
infect
model
bioethic
safeti
paramet
meet
extern
object
criteria
explor
network
cro
breadth
servic
global
reach
provid
part
larger
strateg
outsourc
strategi
especi
earli
develop
risk
high
seek
new
approach
outbreak
cessat
vaccin
anim
zoonot
diseas
use
licens
vaccin
potenti
crossprotect
enhanc
pursu
prototypepathogen
prioritypathogen
approach
use
predevelop
vaccin
platform
speed
develop
note
ad
review
defin
overal
govern
leadership
structur
implement
coher
sustain
strategi
develop
countermeasur
potenti
emerg
infecti
diseas
across
nation
boundari
necessari
invest
author
resourc
note
ad
review
leverag
new
tool
commun
social
media
address
epidem
surveil
respons
determin
way
build
trust
affect
popul
outbreak
develop
regulatori
innov
preepidem
regulatori
converg
expedit
regulatori
requir
epidem
summit
end
group
war
game
exercis
particip
divid
two
team
task
develop
countermeasur
environ
variabl
risk
toler
financ
timelin
exercis
although
somewhat
simplist
design
power
demonstr
consider
room
rethink
assess
risk
find
opportun
effici
exampl
develop
speed
come
countermeasur
develop
import
takehom
point
summar
box
consider
enthusiasm
close
summit
addit
similar
interact
futur
import
addit
defin
tangibl
deliver
also
agre
pool
expert
need
broaden
includ
financ
ethic
intern
polit
meet
activ
plan
opinion
assert
contain
herein
privat
view
author
constru
reflect
offici
view
respect
organ
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
